This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Department of Pharmaceuticals (DoP) has issued a new Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, permitting pharmacompanies to provide brand reminders such as informational and education items and free samples to medical professionals with restrictions on sample packs and total value.
At 99% of pharmacompanies, that's a huge no-no. On top of this, “the company also revealed that the Federal Trade Commission and the Securities and Exchange Commission had opened two new, separate investigations into the troubled biotech. At 99% of pharmacompanies, that’s a huge no-no.
Pharmacompanies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research. During the course of my treatments and my trials, and afterwards, I was the expert in how I wanted to manage my life.”.
The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact.
The drug led to impressive blood sugar and body weight drops in clinical trials. The approval for tirzepatide—which Lilly will market under the brand name Mounjaro—isn’t for weight loss but Type 2 diabetes. Food and Drug Administration approved Eli Lilly’s novel treatment for diabetes. A matter of trust?
Introduction In todays digital-first world, content marketing campaigns are no longer optional for pharmaceutical brands. Imagine content marketing as the heartbeat of a pharmabrands digital presence. So, how can pharmacompanies use content marketing to engage HCPs and patients effectively ? Lets dive in.
Last year, the company added clinical trials to the list with the launch of CVS Health Clinical Trial Services , an initiative that works with pharmacompanies on clinical trial recruitment and even hosts trial sites at certain retail locations. This interview has been edited for length and clarity.
SUMMARY: Doctors said they were dissatisfied were marketing emails (46%), telephone sales calls with sales reps (42%), and both webinars and websites (each at 39%) from pharmacompanies, according to Indegene. Your physician audience should be segmented by parameters that are important to the success of your brand.
This strategic move transformed Actavis into one of the largest pharmacompanies globally, with a strong presence across branded, generic and over-the-counter (OTC) medicines. Following the merger, Actavis rebranded itself as Allergan, leveraging the strong recognition of Allergans brand.
Pharmacompanies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double helix that it says reflects its commitment to breakthrough science. It’s a dynamic reflection of our purpose. pic.twitter.com/vNqCgWus4w.
In recent years, pharmacompanies have invested heavily in their healthcare provider (HCP) portals, along with other digital solutions, to account for the reduction in face-to-face time between reps and HCPs during and post-pandemic. What is meant by an HCP portal? How can this impact patient care?
So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%). I have worked with and stayed in contact with some R&D people within pharma and they have a different answer. In pharma R&D returns have declined to 1.8 percent—a slight decrease of 0.1
Roche’s Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous formulation, after the new version matched the original intravenous formulation in a phase 3 trial. Results from a trial in first-line NSCLC are due in early 2023.
In 2019, drugs within the oncology therapeutic area accounted for $143 billion in branded pharmaceutical sales, equalling approximately 20% of all global pharmaceutical sales, according to McKinsey. One of the means of more quickly discovering and progressing R&D candidates that pharma is looking into is AI technology.
With millions of healthcare professionals (HCPs) and patients active on platforms like LinkedIn, Twitter, Facebook, and Instagram, pharmabrands can no longer afford to stay silent. Effective social media strategies allow pharmacompanies to: Build trust with HCPs and patients. Short video clips with expert insights.
In addition, both companies would be able to focus on maximising value creation for their shareholders by prioritising capital and resource allocation, employing separate capital structure policies, and increasing management focus on their respective business needs.”. The company had revenues of $9.6bn both in 2020 and last year.
Whether you’re a large pharmacompany or a small, emerging one, communication is key. Mark has developed the commercial strategy and leading market access, marketing and multi-channel sales teams at launch for a German biotech company, CO.DON AG, a specialized leader in cell therapies.
The combined company will operate under the BehaVR brand, and starts operations with a $13 million cash injection from a Series B financing led by Oxford Science Enterprises and Optum Ventures with participation from Confluent Health, Accenture Ventures, Chrysalis Ventures, and Thornton Capital.
Among these, influencer marketing has emerged as a powerful tool for pharmacompanies seeking to build trust and foster engagement with their target audiences. By leveraging influencer networks, pharmaceutical brands can effectively convey their messages, promote their products, and ultimately improve patient outcomes.
Armed with these insights, life sciences companies can develop patient-centric solutions that will lead to more successful products. Taking an engaged approach has clear benefits, including improved trial retention and development of PROs that can support market-entry and market access. Read the full article here.
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharmacompanies in the world: AstraZeneca.
In many cases, pharmacompanies select a contract development and manufacturing organisation (CDMO) to develop products versus doing the work themselves for reasons related to cost, convenience, and capacity. PDF scale and reformulation challenge manufacturers. Innovative solutions to complex challenges.
By most measures the single largest pharmacompany in the world, US-based Johnson & Johnson (J&J) is also arguably one of the most well-known drugmakers among the general public. . The acquisition included worldwide leading brands such as Listerine oral care products and the Nicorette line of smoking cessation treatments.
It powers drug discovery, clinical trials, and operational performance. Pharmacompanies generate lots of data and bring in other data to support their actions but not all of it gets used which is where we come in,” says Thomas Kurian, head of new markets at Treasure Data, which powers some of the largest companies in pharmaceuticals. “The
How do you position your brand as a force for good while addressing public concerns? Think of Big Pharma as a lighthouse: its purpose is to guide and protect, but if the light isn’t clear, it can be misinterpreted. The company shared real-time updates about vaccine development, clinical trial results, and manufacturing timelines.
Digital advertising campaigns allow pharmaceutical brands to connect with their audiences at critical moments in the healthcare journey. How Digital Ads Are Changing Pharma Marketing Precision Targeting : AI and data analytics allow ads to be shown to HCPs based on specialty, prescribing behavior, and practice location.
Digital advertising campaigns allow pharmaceutical brands to connect with their audiences at critical moments in the healthcare journey. How Digital Ads Are Changing Pharma Marketing Precision Targeting : AI and data analytics allow ads to be shown to HCPs based on specialty, prescribing behavior, and practice location.
In the second quarter alone the vaccine, branded as Comirnaty, raked in $7.8 Disappointing late-stage trials of CureVac’s jab meant there was no competitive advantage, while Sanofi said the dominance of current vaccines made penetration in the market difficult. Meanwhile, China and Russia have rolled out state-owned vaccines.
Consultations and clinical trials are often few and far between. This new information can help pharma increase adherence by improving the quality of treatment and creating patient-centred programs and materials. More frequent data points are needed to get the whole picture on rare diseases.
But how can pharmabrands optimize their digital assets while staying compliant with industry regulations? Imagine a pharma website as a digital waiting room. By refining user experience, messaging, and engagement strategies, pharmacompanies can increase prescription intent, patient adherence, and HCP interaction rates.
Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. How big pharma tackles rare diseases.
Today, digital platforms like LinkedIn and Instagram connect brands with healthcare professionals (HCPs) and patients alike. Patient-Centric Approaches: The shift towards patient empowerment has revolutionized the way pharmabrands communicate. How can pharmacompanies personalize their campaigns?
After the war, Pfizer continued to focus on industrial chemicals as much as medicines, producing the citric acid needed for the emerging soft drinks industry, fuelling brands like Coca Cola and Dr Pepper’s expansion in the 1880s. Likewise, tanezumab, an anti-osteoarthritic, failed in trials. No signs of slowing down.
Understanding Cost-Per-Action in Pharma Cost-Per-Action (CPA) is a performance-based advertising model where advertisers pay only when a specific action is completed. How It Works: Pharmacompanies define an “action,” such as an HCP downloading a clinical study or a patient enrolling in a treatment program.
Rewind to March of 2020, and pharmacompanies were facing a communication crisis. Thankfully, many pharmacompanies had already started on a journey towards digital engagement, and healthcare professionals (HCPs) are embracing the medium more than ever before, thanks in part to newer generations who are increasingly digitally-savvy.
A London high court judge ruled this week that the damages paid to the NHS for an anticompetitive action by French pharmacompany Servier will not be reduced, despite an eyebrow-raising bid by Servier to lower them by arguing against its own product. This is a relief at a time when most would agree the NHS is quite stretched enough.”.
In light of this, pharma wasted no time throwing some added cash towards TV ads. Taking advantage of the opportunity, the top ten pharmabrands spent 17 percent more on TV ads in April 2020 compared to just a month prior, raising their monthly ad expenditures from $156 million to $183 million. 1. Rybelsus. million and $18.6
report indicating that they accounted for half of the most viewed new brands. No Time to Wait’ Ad Campaign from BMS-Pfizer Features Basketball Legend Kareem Abdul-Jabbar for AFib Awareness As pharma TV advertising remained popular in 2023, so did partnerships between pharmacompanies and celebrities for disease and drug campaigns.
Despite limited clinical evidence, a higher inclination of patients towards marijuana has caused several pharmacompanies and regulatory authorities to look at the medical use of marijuana in a new light. Moreover, now BioSteel has signed Kansas City Chiefs quarterback Patrick Mahomes as the endorser of the brand. and Canada.
Following a worldwide Phase 3 trial of BNT162b2 and results indicating the vaccine to be more than 90 per cent effective in preventing Covid-19 cases where participants have shown no evidence of being infected with coronavirus , Pfizer and BioNTech are anticipating further regulatory decisions and approvals to be made around the world.
A marketing network refers to the interconnected channels and strategies pharmacompanies use to reach their target audiences. Why it Matters Efficient Reach: A well-structured network ensures that branded drugs like Keytruda or Dupixent are promoted effectively to the right audience.
A pharmacompany formerly led by ‘pharma bro’ Martin Shkreli has settled a long-running lawsuit with the US federal government over massive price increases for an off-patent drug treatment for people with an HIV-related disease.
The Phase 3 trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed Covid-19 cases have been accrued. The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19. “We
According to Real Chemistry, there are currently 119 active GLP-1 agonist clinical trials, with 53 in Phases III or IV, across more than 60 potential new indications for GLP-1 treatment.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content